At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01801 INNOVENT BIO
Not Yet Opened 10-06 16:08:03
99.350
+2.050
+2.11%
High100.200Low97.900Vol7.30M
Open99.350D1 Closing97.300Amplitude2.36%
Mkt Cap173.37BTradable Cap173.37BTotal Shares1.75B
T/O724.85MT/O Rate0.42%Tradable Shares1.75B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Major Drugmakers Turn to China for Licensing Deals
Reuters  ·  10-02
Major Drugmakers Turn to China for Licensing Deals
Movement Alert｜INNOVENT BIO Falls 3.47% in Regular Trading, Trading at HK$92.9
Market Focus  ·  10-02
Movement Alert｜INNOVENT BIO Falls 3.47% in Regular Trading, Trading at HK$92.9
What IBI3003 Trial Progress Means For Innovent Biologics Stock
Simply Wall St.  ·  10-01
What IBI3003 Trial Progress Means For Innovent Biologics Stock
Major Drugmakers Turn to China for Licensing Deals
Reuters  ·  09-30
Major Drugmakers Turn to China for Licensing Deals
Movement Alert｜INNOVENT BIO Rises 3.18% in Regular Trading, Strong Interim Results and New Drug Approval Boost Sentiment
Market Focus  ·  09-30
Movement Alert｜INNOVENT BIO Rises 3.18% in Regular Trading, Strong Interim Results and New Drug Approval Boost Sentiment
Innovent Says Trispecific Antibody Ibi3003 Posts 84.6% ORR at Phase 1 RP2D in Relapsed/refractory Multiple Myeloma
Reuters  ·  09-29
Innovent Says Trispecific Antibody Ibi3003 Posts 84.6% ORR at Phase 1 RP2D in Relapsed/refractory Multiple Myeloma
2026 Ims Oral Presentation: Innovent Announces Updated Phase 1 Clinical Data of Trispecific Antibody Ibi3003 (Gprc5d/Bcma/Cd3) in Patients with Relapsed or Refractory Multiple Myeloma
THOMSON REUTERS  ·  09-29
2026 Ims Oral Presentation: Innovent Announces Updated Phase 1 Clinical Data of Trispecific Antibody Ibi3003 (Gprc5d/Bcma/Cd3) in Patients with Relapsed or Refractory Multiple Myeloma
US Drugmakers Turn to China for Licensing Deals
Reuters  ·  09-28
US Drugmakers Turn to China for Licensing Deals
Innovent Biologics Gets China Nod for Jaypirca to Treat Chronic Lymphocytic Leukemia
MT Newswires Live  ·  09-28
Innovent Biologics Gets China Nod for Jaypirca to Treat Chronic Lymphocytic Leukemia
Jaypirca® (Pirtobrutinib) Approved in China for a New Indication in Chronic Lymphocytic Leukemia (Cll) /Small Lymphocytic Lymphoma (Sll) Across All Lines of Therapy
Reuters  ·  09-28
Jaypirca® (Pirtobrutinib) Approved in China for a New Indication in Chronic Lymphocytic Leukemia (Cll) /Small Lymphocytic Lymphoma (Sll) Across All Lines of Therapy
Innovent's Jaypirca (pirtobrutinib) wins NMPA approval for all-line CLL/SLL treatment in China
Stock News  ·  09-28
Innovent's Jaypirca (pirtobrutinib) wins NMPA approval for all-line CLL/SLL treatment in China
Innovent Biologics - Jaypirca (Pirtrobrutinib) Approved in China for Cll/Sll Across All Lines of Therapy
THOMSON REUTERS  ·  09-28
Innovent Biologics - Jaypirca (Pirtrobrutinib) Approved in China for Cll/Sll Across All Lines of Therapy
Movement Alert｜INNOVENT BIO Falls 3.31% in Regular Trading, Trading at 96.35 HKD
Market Focus  ·  09-28
Movement Alert｜INNOVENT BIO Falls 3.31% in Regular Trading, Trading at 96.35 HKD
Innovent Expands Phase 3 MarsLight-11 Trial of Ibi363/tak-928 to Include Non-Squamous NSCLC Patients
Reuters  ·  09-28
Innovent Expands Phase 3 MarsLight-11 Trial of Ibi363/tak-928 to Include Non-Squamous NSCLC Patients
Innovent Announces Expansion of Global Phase 3 Marslight-11 Study of Ibi363/Tak-928 (Alpha-Biased Il-2/Pd-1 Bispecific Fusion Protein) in Immunotherapy-Resistant Nsclc to Include Patients with Non-Squamous Nsclc
THOMSON REUTERS  ·  09-28
Innovent Announces Expansion of Global Phase 3 Marslight-11 Study of Ibi363/Tak-928 (Alpha-Biased Il-2/Pd-1 Bispecific Fusion Protein) in Immunotherapy-Resistant Nsclc to Include Patients with Non-Squamous Nsclc
Movement Alert｜INNOVENT BIO Falls 3.29% in Regular Trading, Trading at 100.1 HKD
Market Focus  ·  09-24
Movement Alert｜INNOVENT BIO Falls 3.29% in Regular Trading, Trading at 100.1 HKD
INNOVENT BIO Posts Robust Growth on Dual Momentum From Oncology and Integrated Product Lines
Deep News  ·  09-23
INNOVENT BIO Posts Robust Growth on Dual Momentum From Oncology and Integrated Product Lines
Innovent to Present Phase 3 Interim Data for Cldn18.2 ADC Ibi343 in Third-Line Gastric Cancer at ESMO 2026
Reuters  ·  09-23
Innovent to Present Phase 3 Interim Data for Cldn18.2 ADC Ibi343 in Third-Line Gastric Cancer at ESMO 2026
Market Chatter: US Considers Rules Allowing American Investment in Chinese Drugs
MT Newswires Live  ·  09-21
Market Chatter: US Considers Rules Allowing American Investment in Chinese Drugs
Citi Highlights Policy Boost for Innovative Drugs and Medical Devices, Names Key Sector Picks
Stock News  ·  09-21
Citi Highlights Policy Boost for Innovative Drugs and Medical Devices, Names Key Sector Picks

Introduction

Company Name.
INNOVENT BIO
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Innovent Biologics Inc is an investment holding company principally engaged in the research, development, production and sales of innovative medicines for the treatment of diseases such as cancer, cardiovascular and metabolic (CVM), autoimmune and eye diseases. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The Company mainly conducts its businesses within domestic and overseas markets.
Issue price:
--